Combination of TATE and PD-1 Inhibitor in Liver Cancer
A phase 2 trial of Nivolumab in hepatocellular carcinoma, run by Teclison Ltd., now recruiting.
Overview
Combination of TATE and PD-1 Inhibitor in Liver Cancer is a phase 2 interventional study registered as NCT03259867 by Teclison Ltd., with 54 participants planned, started 2017-07-01 and due to reach its primary completion in 2026-12-30. Interventions recorded: Nivolumab Injectable Product, Trans-arterial tirapazamine embolization. Conditions listed: Hepatocellular Carcinoma, Gastric Cancer. No results are recorded here; the registry entry is the source.
Similar pages
not linked directly; found by shared links- TrialCVM-1118 in Combination With Nivolumab for Unresectable Advanced Hepatocellular Carcinoma
Shares Nivolumab, Hepatocellular carcinoma.
- TrialA Study of Nivolumab in Participants With Hepatocellular Carcinoma Who Are at High Risk of Recurrence After Curative Hepatic Resection or Ablation
Shares Nivolumab, Hepatocellular carcinoma.
- TrialCheckMate 9DW
Shares Nivolumab, Hepatocellular carcinoma.
- IdeaImmunotherapy downstaging to transplant with a safe washout
Shares Nivolumab, Hepatocellular carcinoma.
- TrialVisugromab, Nivolumab and Lenvatinib Compared to Double Placebo and Lenvatinib in Unresectable or Metastatic Hepatocellular Carcinoma Post Anti-PD-(L)
Shares Nivolumab, Hepatocellular carcinoma.
- PersonIgnacio Melero
Shares Nivolumab, Hepatocellular carcinoma.
- InstitutionIstituto Nazionale Tumori IRCCS Fondazione G. Pascale
Shares Nivolumab, Hepatocellular carcinoma.